All data were tested for normality using Shapiro wilk
When compared with placebo or other therapies, GLP-1 agonists were associated with an increased risk of biliary disease [23]: Overall biliary disease: RR 1.37(95% CI 1.231.52) Cholelithiasis: RR 1.27 (95% CI 1.101.47) Cholecystitis: RR 1.36 (95% CI 1.141.62) Mechanisms: Reduced gallbladder motility Rapid weight loss increased cholesterol saturation and gallstone formation
While GLP-1s clearly are effective for weight loss, experts may be concerned if their patients do not make other lifestyle changes, for example, changing their diet or being more active
Unlike many nutrients, it passes through the upper digestive system largely intact
[DOI] [PubMed] [Google Scholar] 453.de Caprona M.D., Beisel K.W., Nichols D.H., Fritzsch B
Pharmacologic approaches to glycemic treatment: standards of medical care in Diabetes-2022